Silence Therapeutics (NASDAQ:SLN) Shares Down 6.9% – What’s Next?

Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN)’s share price fell 6.9% during trading on Wednesday . The stock traded as low as $13.60 and last traded at $13.70. 3,559,474 shares were traded during trading, an increase of 595% from the average session volume of 512,178 shares. The stock had previously closed at $14.72.

Analyst Ratings Changes

Several research firms recently commented on SLN. Morgan Stanley raised their target price on Silence Therapeutics from $25.00 to $32.00 and gave the stock an “overweight” rating in a research note on Tuesday. HC Wainwright reissued a “buy” rating and issued a $75.00 price target on shares of Silence Therapeutics in a research note on Wednesday, June 17th. Weiss Ratings restated a “sell (d-)” rating on shares of Silence Therapeutics in a report on Friday, July 17th. Finally, Cantor Fitzgerald began coverage on shares of Silence Therapeutics in a research report on Wednesday, June 24th. They set an “overweight” rating for the company. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $53.50.

Silence Therapeutics Trading Down 5.8%

The stock’s 50-day moving average price is $9.66 and its 200-day moving average price is $7.31. The company has a market cap of $654.68 million, a P/E ratio of -10.83 and a beta of 1.39.

Silence Therapeutics (NASDAQ:SLN) last issued its earnings results on Monday, August 10th. The company reported ($0.26) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.12). Silence Therapeutics had a negative net margin of 8,943.86% and a negative return on equity of 96.82%. On average, research analysts anticipate that Silence Therapeutics PLC Sponsored ADR will post -1.08 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Silence Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of SLN. GAMMA Investing LLC raised its position in shares of Silence Therapeutics by 18.1% during the second quarter. GAMMA Investing LLC now owns 11,063 shares of the company’s stock worth $121,000 after purchasing an additional 1,698 shares during the period. Seven Fleet Capital Management LP grew its position in Silence Therapeutics by 6.2% in the 1st quarter. Seven Fleet Capital Management LP now owns 156,759 shares of the company’s stock valued at $826,000 after purchasing an additional 9,159 shares during the period. Bank of America Corp DE increased its stake in Silence Therapeutics by 903.8% during the 1st quarter. Bank of America Corp DE now owns 29,773 shares of the company’s stock valued at $157,000 after purchasing an additional 26,807 shares in the last quarter. ADAR1 Capital Management LLC increased its stake in Silence Therapeutics by 628.2% during the 1st quarter. ADAR1 Capital Management LLC now owns 172,157 shares of the company’s stock valued at $907,000 after purchasing an additional 148,514 shares in the last quarter. Finally, SG Americas Securities LLC raised its holdings in Silence Therapeutics by 11.8% during the first quarter. SG Americas Securities LLC now owns 286,698 shares of the company’s stock worth $1,511,000 after buying an additional 30,358 shares during the last quarter. Institutional investors own 98.73% of the company’s stock.

Silence Therapeutics Company Profile

Silence Therapeutics plc is a clinical-stage biotechnology company focused on the discovery and development of ribonucleic acid interference (RNAi) therapeutics. Leveraging its proprietary EnCore lipid nanoparticle delivery platform, the company aims to silence disease-causing genes in the liver and other tissues. Silence’s technology is designed to enhance targeted delivery of small interfering RNA (siRNA) molecules, with the goal of achieving durable therapeutic effects and improved safety profiles compared with traditional drug modalities.

The company’s lead product candidates include SLN360, an siRNA therapeutic designed to reduce lipoprotein(a) levels for cardiovascular risk reduction, and SLN124, aimed at treating hereditary hemochromatosis and beta-thalassemia by modulating iron metabolism.